DAFTAR PUSTAKA
1. World Health Organization, WHO World Health Organization Report 2000, Genewa: WHO; (2001)
2. World Health Organization. Deaths from Coronary Heart Disease.
(2008). Available from
3. Deitcher SR, Rodgers GM.Thrombosis and antithrombotic therapy. In : Greer JP, Foerster J, Lukens JN, et al. Wintrobe`s Clinical Hematology. 11th
4. Manurung D.Patogenesa terkini dari Sindroma Koroner Akut. Prosiding Simposium Pendekatan Holistik Penyakit Kardiovaskuler II. Balai
Penerbit Bagian Ilmu Penyakit Dalam FK UI. Jakarta. 2003; 63-69.
ed. Lippincott Williams and Wilkins. USA. 2004:1714-18.
5. Guran O, Akalin F, Ayabakan C, et al.High-sensitivity C-reactive protein in children at risk for coronary arterydisease. Acta Pediatrica. 2007:96;1214-1219
6. Libby P. The Pathogenesis of atherosclerosis. In : Kasper D, Braunwald E, Fauci A,et al.ed. Harrison’s Principles of Internal Medicine,16th
7. Kasap S, Gonenc A, Sener D.E. and Hisar I.Serum cardiac markers in patients with acute myocardialinfarction: oxidative stress, C-Reactive protein and Nterminalprobrain natriuretic peptide. Journal of ClinicalBiochemistry and Nutrition. 2007: 41; 50-57.
eds. Mc Graw Hill. 2005;1425-1429
induced ST segment depression after infarction. Br Heart J. 1987: 57; 133-8
9. Majid A. Penyakit jantung koroner : patofisiologi, pencegahan dan
pengobatan terkini. Pidato pengukuhan guru besar tetap dalam bidang
ilmu Fisiologi pada Fakultas Kedokteran Universitas Sumatera Utara. USU press. 2007
10. Raymond J. Gibbons, Jonathan Abrams, Kanu Chatterjee, Jennifer Daley, Prakash C. Deedwania et al.Guideline Update for the Management of Patients With Chronic Stable Angina. ACC/AHA 2002.
Available from
11. Gibbons RJ. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina --summary article : a report of the american college of cardiology/american heart association task force on practice guidelines (committee on the management of patients with chronic stable angina). Circulation. 2003:107; 149-158
http://www.cardiosource.com/guidelines/guidelines/stable/stable
12. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H, Pachinger O, Mair J. Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease. Heart. 2009:95; 297–303
14. Valentin Fuster, R. Wayne Alexander, Robert A. O' Rourke. Cardiac catheterization, cardiac angiography and coronary blood flow and pressure measurements. In Hurst's The Heart. 2004:17; 483-537
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005:352; 1685-95
16. Ross R. Atherosclerosis - an inflammatory disease, N Eng J Med. 1999: 340; 115–26
17. Packard RRS, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clinical Chemistry. 2008:54; 24-38.
18. Buffon A, Biasucci LM, Liuzzo GD, Onofrio G, CreaFand Maseri A. Widespread coronary inflammationin unstable angina. The New England Journal of Medicine. 2002:347; 5-12.
19. Thakur S, Gupta S, Parchwani H, Shah V, Yadav V (2011).Hs-CRP: a potential marker for coronary heart disease. Indian Journal of Fundamental and Applied Life Science. 2011:1; 1-4
20. Razzouk L. C-reactive protein predicts long-term mortality independently
of low-density lipoprotein cholesterol in patients undergoing
percutaneous coronary intervention. Am Heart J. 2009: 158; 277-83
21. Daniel G, Hackam Sonia S. Anand. Emerging risk factors for atherosclerotic disease: A critical review of the evidence. Journal of American Heart Association. 2003:290; 932-940.
23. Marcovina SM, Koschinky ML. Lipoprotein(a) as a risk factor for coronary artery disease. American J Cardiology. 1998: 82; (12A)
24. Scanu AM. The role of Lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep. 2001:3(5); 385-90
25. Dahlen GH. Incidence of lipoprotein(a) among population, in Scanu AM. Ed. Lipoprotein(a). San Diego Toronto,Tokyo, American press Inc. 1990;183-204
26. Nagayama M, Yukito S, Nagayama T.Lipoprotein(a) and ischemic cerebrovascular disease in young adult. Stroke. 1994:25; 74-8
27. Uterman G. The misteri of lp(a). Science. 1989:246; 904-10
28. Shahid HS. Serum high-sensitivity C-reactive protein and lipoprotein(a) levels: a comparison between diabetic and non-diabetic patients with coronary artery disease. Med J Malaysia. 2011: 66; 113-116
29. Hasnat MA, Islam Aemm, Chowdhury AW, Khan Hilr, Hosan MZ. High sensitivity C-reactive protein (hs-CRP) and its correlation with angiographic severity of patient with coronary artery disease. J Dhaka Med Coll. 2010:19; 91-97
30. Jalali BA, Rafie M, Mozaffari H. Lipoprotein(a) as a strong risk factor for coronary artery disease in iranian population. Medical Journal of Islamic.
2000:13; 5-9
32. Bucova M and Nikolitsa Pappa. C - Reactive protein, cytokines and inflammation in cardiovascular disease. Bratis1 Lek Listy. 2008:109; 333- 40
33. Eleni S. Nakou ES, Evangelos N. Liberopoulos et al. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.
Current Vascular Pharmacology. 2008:6;258-70
34. McGill HC, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. (2000). Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000:72; 1307S-15S
35. Desideri G, De Simone M et al. Early activation of endothelial cells and platelets in obesitas children. J Clin Endocrinol Metab. 2005:90; 3145-52 36. Kavazarakis E, Moustaki M, Gourgiotis D. The impact of serum lipid
levels on circulating soluble adhesion molecules in childhood. Pediatr Res. 2002:52; 454-8
37. Koenig W. C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant. 2003:18; 1039–41 38. Wangko LC, Budiono B, Lefrandt RL. Angiografi koroner indikasi,
kontraindikasi, dan proteksi terhadap radiasi. J Biomedik. 2012;4(3) Abstrak
39. Scanu AM. Structural and functional polymorphism of lipoprotein(a) biological and clinical implications. Clinical Chemistry. 1995:41(1);170-2. NACB Symposium
41. Butman BT, Taddei-Peters WC, Ransom JH. Lipoprotein(a) as a marker for atherosclerotic disease. Clinical Hemostasis review. 1993 42. Scanu AM, Fless GM. Lipo (a) heterogenicity and biological relevance. J
clinical Invest. 1990:85; 1709-15
43. Berg K. Lp(a) Lipoprotein : an overview, In : Scanu AM. Lipoprotein(a).
Academic press inc. San Diego,Toronto.Tokyo. 1990; 1-20
44. Ridker PM. Plasma concentration of lipoprotein and the risk of future.Stroke. JAMA. 1995; 273
45. Scanu AM. Lipoprotein(a) and atherosclerosis. Annals of Internal Med.1991:115; 209-18
46. Scott J. Lipoprotein(a) Thrombotic and atherogenic. BMJ. 1995:303; 663-4
47. Galton J, Krone W. Hyperlipidaemia in Practice. Gower Medical Publishing. London. 8-9.1991
48. Borque L. Automated Latex Nephelometric Immunoassay for the Measurement of Serum Lipoprotein(a). Journal Clin Lab Anal. 1993: 7(2); 105-10
49. William RH. Radioimmunoassay of human plasma Lp(a) lipoprotein.
Journal of Lipid Research. 1997:18; 331-338
50. Nguyen TT. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997:96; 1390-1397. 51. Torres MB.Rapid Detection of Elevated Serum Lipoprotein(a) Levels :
52. Stanley J. Instrumentation. In : Stanley J (eds). Essentials of Immunology & Serology. Thomson Delmar Learning. Columbia. 2002; 133-48
53. Libby P, Ridker PM. Inflammation and atherosclerosis: role of creactive protein in risk assessment. Am J Med. 2004:116; 9-16
54. Vermeire S,Van Assche G,Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflammatory Bowel Diseases. 2004:10; 661-5.
55. Meier-Ewert HK, Ridker PM, Rifai N. Absence of diurnal variation of Creactive protein concentrations in healthy human subjects.Clin Chem. 2001:47; 426–430
56. Gotschlich E. C-reactive protein: a historical overview. Annals of the New York Academy of Sciences. 1989:557; 9-18.
57. Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. Journal of Cardiology. 2009:53; 317-33
58. Danesh J, Pepys MB. C-Reactive protein and coronary disease: is there a causal link?. Circulation. 2009:120; 2036-39
59. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB . C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008: 264; 295–314
61. Delanghe J, Langlois M, De Bacquer D. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease.
Atherosclerosis. 2002:160(2); 471-6
62. Pearson TA, George A. Mensah. Markers of inflammation and cardiovascular disease. application to clinical and public health practice a statement for healthcare professionals from the centers for disease control and prevention and the american heart association. aha/cdc scientific statement. Circulation. 2003:107; 499-511.
63. Handojo Indro. Immunoassay Terapan pada Beberapa Penyakit Infeksi.
Ed 1, Airlangga University Press, Surabaya, 2004; 272-285
64. Loho T. Pemeriksaan laboratorium pada stroke. Dalam: Pendidikan Berkesinambungan Patologi Klinik, ed 1. Penerbit FKUI. 2008; 57-70 65. Henry JB. Clinical Diagnosis and Management by Laboratory Methods,
ed 20, Saunders. Philadelphia. 2001; 259-262
66. Roche. Roche Diagnostic GmbH. CRP. Product Information. 2003
67. Tietz. Clinical Chemistry and Molecular Diagnostics, ed 4. Saunders Missouri. 2006; 543-546
68. Nyandak T, Gogna A, Bansal S, Deb M. High Sensitive C-Reactive Protein (hsCRP) and its Correlation with Angiographic Severity of Coronary Artery Disease (CAD). JIACM. 2007;8(3):217-21
70. Dwitaryo AB. Endotelium: Target Terapi untuk Penyakit Kardiovaskuler. Dalam : Tanuwidjojo S, Rifqi S. Atherosclerosis From Theory to Clinical Practice, Naskah lengkap Cardiology-Update Semarang, 2003 : p71-81 71. Soeharto I. Penyakit Jantung Koroner dan Serangan Jantung. Jakarta:
PT. Gramedia Pustaka Utama; 2004: 61-62
72. Heart-health screenings. American heart association [Internet]. 2011. [cited 2013 Okt 3]. Available from:
Screenings_UCM_428687_Article.jsp#.TxegnNUqt0c
73. Price SA. Penyakit aterosklerotik koroner. Dalam: Wijaya C editor.
Patofisiologi Konsep Klinis Proses-Proses Penyakit. Edisi 4. Jakarta: Penerbit buku kedokteran EGC; 1994:528-556
74. Coronary heart disease risk factors. National Heart Lung and Blood Institute [Internet]. 2011. [cited 2011 Dec 14]. Available from:
75. Adam JMF . Manfaat penurunan Berat Badan pada Obese dengan komplikasi Metabolik. Dalam: Djokomoeljanto R, Darmono, Suhartono T, Pambayun TGD editor. Naskah Lengkap Kongres Nasional V PERSADIA dan PITPERKENI. Semarang: Badan Penerbit UNDIP; 2002: 15-24
77. Azita F, Toba K, Asghar Z. et al. Comparison of lipoprotein(a) and apolipoproteins in Children with and without familial history of premature coronary artery disease. Iran J Pediatr, 2008;18 (2):159-162
78. Dutta J, Solankiz US. Lipoprotein(a) and lipid levels in children with andwithout family history of premature ischemic heartdisease. World Journal of Pharmacy and Pharmaceutical Sciences,2013; 2 (6): 5811-5819
79. Murat SN, Karadeniz M, Akyel A, et al. Relationship of high-sensitive C-reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: An Indian perspective. Indian heart journal.2013; 165 : 357-367
80. Cowie, M.R., Dar, Q. The Epidemiologyand Diagnosis of Heart Failure. In: Fuster,V., et al., eds. Hurst’s the Heart. 12th ed.Volume 1. USA: McGraw-Hill, 2008: 713
81. Yuliani F, Oenzil F, Iryani D. Hubungan berbagai faktor risiko terhadap kejadian penyakit jantung koroner pada penderita diabetes mellitus tipe 2. Artikel Penelitian.Jurnal Kesehatan Andalas.2014; 3(1): 37-40
82. Ghodke SS, Padalkar RK, Bhagat SS, Ghone RA, Patil SM. hs- CRP: A “Golden Marker” of Inflammation and Coronary Artery Disease.
International Journal of Health Sciences & Research. 2012; 2 (6): 42-46 83. Farhan HA, Al-Safar HB. Coronary Artery Disease: Conventional
84. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss.J Am Coll Cardiol.2009;53(21):1925-1932.
85. Jin J. Obesity and the Heart, The definition of obesity is based on body mass index (BMI),a number calculated from a person’s height and weight.JAMA. 2013; 310 (19): 2113